Research Article
Year 2023,
Volume: 45 Issue: 1, 81 - 86, 31.03.2023
An Erratum to this article was published on October 9, 2024. http://cmj.cumhuriyet.edu.tr/en/pub/cmj/issue/87638/1412591
Abstract
Objective: The new type of Coronavirus (SARS-CoV-2) damages cells by using the angiotensin converting enzyme-2 (ACE2) as a receptor to adhere and go through the cell membrane. It is known that some of the endocrine organs express ACE2 and these organs are potential targets for Coronavirus 2019 disease (Covid-19). This study aimed to investigate the effect of coronavirus disease 2019 (Covid-19) on Fluorine-18 fluorodeoxyglucose (18F-FDG) uptake of endocrine system organs.
Methods: Sixteen patients who had Covid-19 underwent 18F-FDG positron emission tomography/computed tomography (PET/CT) later, 77 patients who did not have Covid-19 underwent 18F-FDG PET/CT between March 2020-October 2021 were analyzed finally. SUVmax and SUVmean of the pituitary, thyroid, adrenal gland, pancreas, and testis measured from the PET/CT of the patients had Covid-19 were compared with SUVmax, and SUVmean measured from the same organs in PET/CT images of the patients who had not Covid-19.
Results: Pancreatic mean SUVmax was significantly higher in patients who had Covid-19 than in patients who did not (p= 0.035). Pancreatic mean SUVmean was slightly higher in patients who had Covid-19 than in patients who did not, but this difference was not statistically significant (p= 0.072). No significant difference was found between the SUVmax and SUVmean values of the pituitary gland, thyroid gland, adrenal gland, and testis in patients who had Covid-19 and did not have.
Conclusions: It was thought that the pancreas might have been affected in the course of Covid-19 due to the higher mean SUVmean values of the pancreas in patients who had Covid- 19.
Keywords
References
- Sanyal S. How SARS-CoV-2 (COVID-19) spreads within infected hosts - what we know so far. Emerg Top Life Sci. 2020;4:371-8.
- Wang X, Powell CA. How to translate the knowledge of COVID-19 into the prevention of Omicron variants. Clin Transl Med. 2021;11:e680.
- Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, Planchais C, Porrot F, Robillard N, Puech J, Prot M, Gallais F, Gantner P, Velay A, Le Guen J, Kassis-Chikhani N, Edriss D, Belec L, Seve A, Courtellemont L, Péré H, Hocqueloux L, Fafi-Kremer S, Prazuck T, Mouquet H, Bruel T, Simon-Lorière E, Rey FA, Schwartz O. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596:276-280.
- Abdool Karim SS, de Oliveira T. New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications. N Engl J Med. 2021;384:1866-68.
- Johnson KD, Harris C, Cain JK, Hummer C, Goyal H, Perisetti A. Pulmonary and Extra-Pulmonary Clinical Manifestations of COVID-19. Front Med (Lausanne). 2020;7:526.
- Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19). J Gen Intern Med. 2020;35:1545-49.
- Lisco G, De Tullio A, Jirillo E, Giagulli VA, De Pergola G, Guastamacchia E, Triggiani V. Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects. J Endocrinol Invest. 2021;44:1801-14.
- Speer G, Somogyi P. Thyroid complications of sars and coronavirus disease 2019 (Covid-19). Endocr J. 2021;68:129–36.
- Mongioì LM, Barbagallo F, Condorelli RA, Cannarella R, Aversa A, La Vignera S, Calogero AE. Possible long-term endocrine-metabolic complications in COVID-19: lesson from the SARS model. Endocrine. 2020;68:467–70.
- Lania A, Sandri MT, Cellini M, Mirani M, Lavezzi E, Mazziotti G. Thyrotoxicosis in patients with COVID-19: The THYRCOV study. Eur J Endocrinol. 2020;183:381–7.
- Scappaticcio L, Pitoia F, Esposito K, Piccardo A, Trimboli P. Impact of COVID-19 on the thyroid gland: an update. Rev Endocr Metab Disord. 2021;22:803–15.
- Wang F, Wang H, Fan J, Zhang Y, Wang H, Zhao Q. Pancreatic Injury Patterns in Patients With Coronavirus Disease 19 Pneumonia. Gastroenterology. 2020;159:367–70.
- Bruno G, Fabrizio C, Santoro CR, Buccoliero GB. Pancreatic injury in the course of coronavirus disease 2019: A not-so-rare occurrence. J Med Virol. 2021;93:74–5.
- Liu F, Long X, Zhang B, Zhang W, Chen X, Zhang Z. ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection. Clin Gastroenterol Hepatol. 2020;18:2128-30.
- Kusmartseva I, Wu W, Syed F, Van Der Heide V, Jorgensen M, Joseph P, Tang X, Candelario-Jalil E, Yang C, Nick H, Harbert JL, Posgai AL, Paulsen JD, Lloyd R, Cechin S, Pugliese A, Campbell-Thompson M, Vander Heide RS, Evans-Molina C, Homann D, Atkinson MA. Expression of SARS-CoV-2 Entry Factors in the Pancreas of Normal Organ Donors and Individuals with COVID-19. Cell Metab. 2020;32:1041-51.
- Hadi A, Werge M, Kristiansen KT, Pedersen UG, Karstensen JG, Novovic S, Gluud LL. Coronavirus Disease-19 (COVID-19) associated with severe acute pancreatitis: Case report on three family members. Pancreatology. 2020;20:665-7.
- Eldaly AS, Fath AR, Mashaly SM, Elhadi M. Acute pancreatitis associated with severe acute respiratory syndrome coronavirus-2 infection: a case report and review of the literature. J Med Case Rep. 2021;15: 1–12.
- Aloysius MM, Thatti A, Gupta A, Sharma N, Bansal P, Goyal H. COVID-19 presenting as acute pancreatitis. Pancreatology. 2020;20:1026-7.
- Albano D, Treglia G, Giovanella L, Giubbini R, Bertagna F. Detection of thyroiditis on PET/CT imaging: a systematic review. Hormones. 2020;19:341–9.
- Frara S, Allora A, Castellino L, di Filippo L, Loli P, Giustina A. COVID-19 and the pituitary. Pituitary. 2021;24:465–81.
Year 2023,
Volume: 45 Issue: 1, 81 - 86, 31.03.2023
An Erratum to this article was published on October 9, 2024. http://cmj.cumhuriyet.edu.tr/en/pub/cmj/issue/87638/1412591
Abstract
References
- Sanyal S. How SARS-CoV-2 (COVID-19) spreads within infected hosts - what we know so far. Emerg Top Life Sci. 2020;4:371-8.
- Wang X, Powell CA. How to translate the knowledge of COVID-19 into the prevention of Omicron variants. Clin Transl Med. 2021;11:e680.
- Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, Planchais C, Porrot F, Robillard N, Puech J, Prot M, Gallais F, Gantner P, Velay A, Le Guen J, Kassis-Chikhani N, Edriss D, Belec L, Seve A, Courtellemont L, Péré H, Hocqueloux L, Fafi-Kremer S, Prazuck T, Mouquet H, Bruel T, Simon-Lorière E, Rey FA, Schwartz O. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596:276-280.
- Abdool Karim SS, de Oliveira T. New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications. N Engl J Med. 2021;384:1866-68.
- Johnson KD, Harris C, Cain JK, Hummer C, Goyal H, Perisetti A. Pulmonary and Extra-Pulmonary Clinical Manifestations of COVID-19. Front Med (Lausanne). 2020;7:526.
- Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19). J Gen Intern Med. 2020;35:1545-49.
- Lisco G, De Tullio A, Jirillo E, Giagulli VA, De Pergola G, Guastamacchia E, Triggiani V. Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects. J Endocrinol Invest. 2021;44:1801-14.
- Speer G, Somogyi P. Thyroid complications of sars and coronavirus disease 2019 (Covid-19). Endocr J. 2021;68:129–36.
- Mongioì LM, Barbagallo F, Condorelli RA, Cannarella R, Aversa A, La Vignera S, Calogero AE. Possible long-term endocrine-metabolic complications in COVID-19: lesson from the SARS model. Endocrine. 2020;68:467–70.
- Lania A, Sandri MT, Cellini M, Mirani M, Lavezzi E, Mazziotti G. Thyrotoxicosis in patients with COVID-19: The THYRCOV study. Eur J Endocrinol. 2020;183:381–7.
- Scappaticcio L, Pitoia F, Esposito K, Piccardo A, Trimboli P. Impact of COVID-19 on the thyroid gland: an update. Rev Endocr Metab Disord. 2021;22:803–15.
- Wang F, Wang H, Fan J, Zhang Y, Wang H, Zhao Q. Pancreatic Injury Patterns in Patients With Coronavirus Disease 19 Pneumonia. Gastroenterology. 2020;159:367–70.
- Bruno G, Fabrizio C, Santoro CR, Buccoliero GB. Pancreatic injury in the course of coronavirus disease 2019: A not-so-rare occurrence. J Med Virol. 2021;93:74–5.
- Liu F, Long X, Zhang B, Zhang W, Chen X, Zhang Z. ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection. Clin Gastroenterol Hepatol. 2020;18:2128-30.
- Kusmartseva I, Wu W, Syed F, Van Der Heide V, Jorgensen M, Joseph P, Tang X, Candelario-Jalil E, Yang C, Nick H, Harbert JL, Posgai AL, Paulsen JD, Lloyd R, Cechin S, Pugliese A, Campbell-Thompson M, Vander Heide RS, Evans-Molina C, Homann D, Atkinson MA. Expression of SARS-CoV-2 Entry Factors in the Pancreas of Normal Organ Donors and Individuals with COVID-19. Cell Metab. 2020;32:1041-51.
- Hadi A, Werge M, Kristiansen KT, Pedersen UG, Karstensen JG, Novovic S, Gluud LL. Coronavirus Disease-19 (COVID-19) associated with severe acute pancreatitis: Case report on three family members. Pancreatology. 2020;20:665-7.
- Eldaly AS, Fath AR, Mashaly SM, Elhadi M. Acute pancreatitis associated with severe acute respiratory syndrome coronavirus-2 infection: a case report and review of the literature. J Med Case Rep. 2021;15: 1–12.
- Aloysius MM, Thatti A, Gupta A, Sharma N, Bansal P, Goyal H. COVID-19 presenting as acute pancreatitis. Pancreatology. 2020;20:1026-7.
- Albano D, Treglia G, Giovanella L, Giubbini R, Bertagna F. Detection of thyroiditis on PET/CT imaging: a systematic review. Hormones. 2020;19:341–9.
- Frara S, Allora A, Castellino L, di Filippo L, Loli P, Giustina A. COVID-19 and the pituitary. Pituitary. 2021;24:465–81.
There are 20 citations in total.
Details
| Primary Language | English |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Medical Science Research Articles |
| Authors | |
| Publication Date | March 31, 2023 |
| Acceptance Date | February 13, 2023 |
| Published in Issue | Year 2023Volume: 45 Issue: 1 |
